Over 80% of candidate drugs have poor solubility, leading to low bioavailability. This challenge slows down pharmaceutical R&D pipelines, delaying availability of drugs to patients in need.
In this white paper, we introduce a Quality-by-Design (QbD) formulation approach to addresses solubility challenges. We discuss the use of key technologies such as lipid-based formulations and amorphous solid dispersions and how integrating QbD from early development can accelerate a drug candidates' journey to market.
Copyright © 2025 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy